An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Foresee Pharmaceuticals
- 12 Dec 2018 This trial has been completed in Lithuania (End date: 2018-11-19)according to European Clinical Trials Database record.
- 06 Dec 2018 This trial has been completed in Czech Republic according to European Clinical Trials Database record.
- 26 Nov 2018 According to a Foresee Pharmaceuticals media release,Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer